Innovate with Confidence through Independent Supercomputing and World-Class AI

Sponsored content brought to you by

AI-discovered molecules, in Phase I trials, are substantially more successful than historic industry averages, according to a study recently published by Elsevier in Drug Discovery Today. AI algorithms are highly capable of generating or identifying molecules with drug-like properties. Add to that a private supercomputing infrastructure spanning 10,000 square meters and you have the power to push new boundaries in drug discovery.

“In the rapidly evolving world of pharmaceuticals, drug discovery is undergoing a seismic shift,” says Jongsun Jung, PhD, CEO of Syntekabio. “AI can learn very quickly, avoid human error, and, when carefully applied, find answers in large, integrated data sets.”

Syntekabio aims to support R&D teams with the enticing possibility of achieving hit discovery in just 3–5 months, optimizing leads in 6–10 months, and advancing to animal testing within 6–12 months. This is a bold ambition in a market currently dominated by big tech players.

To stay on the cutting edge, Syntekabio is continuously refining its algorithms, expanding its compound libraries, and enhancing its computational power. It is integrating more advanced AI models to further shorten discovery timelines and improve accuracy.

The goal is to accelerate the discovery of first-in-class and best-in-class compounds and reduce the time, cost, and risks involved in drug discovery for Syntekabio’s clients to bring important new treatments to patients.

The beauty: Matching chemical keys with protein locks

At the center of Syntekabio’s drug discovery approach is its AI platform, DeepMatcher^®, which utilizes advanced technologies like Flexible Molecular Docking (FMD). When compared to Rigid Molecular Docking (RMD), FMD requires 50–100 times more computational resources to analyze physical interactions between proteins and ligands. The models are trained on these interactions rather than a specific disease. “The advantage of this approach is the ability to plug in almost any protein that will interact with the ligand in a certain way and design a compound that will connect with the target protein in the intended manner,” Dr. Jung explains.

DeepMatcher^® can screen over 10 billion known compounds and uses customized precision discovery modeling to analyze specific use cases. With over 1,400 drug targets that are compatible with in vitro and in vivo testing, Syntekabio’s AI-driven platform helps researchers explore new drug indications, discover new modes of action, and pursue drug repurposing opportunities.

The brawn: 10,000 square meters of computational power

Syntekabio’s Bio-Supercom Center is the cornerstone of the company’s ability to run computationally heavy FMD-driven 3D-CNN models. This state-of-the-art facility houses 5,000 servers, 40,000 CPU cores, and 2,500 GPUs that work to drive the company’s AI algorithms. Syntekabio supplements this digital powerhouse with human know-how, working with a global network of contract research organizations to validate computational results.

“Our technology produces results fast,” Dr. Jung says. “But we also validate our results in a wet lab so our clients can have confidence that the compounds we deliver can be brought into clinical testing.”

The edge: Develop now, pay later with STB LaunchPad

Syntekabio’s STB LaunchPad program, backed by DeepMatcher^®, is designed to produce hits and leads across multiple therapeutic areas. Combined with independent in vivo and in vitro testing, the program can deliver an IND-enabled candidate. Syntekabio has proven its capabilities through several collaborations as well as by producing its own novel molecules.

Syntekabio believes strongly in its capabilities. To prove this, the company is investing in its clients’ success by offering access to its technology with no upfront costs. With this model, a client pays only after obtaining the agreed upon, validated results, making it a strategic, low-risk option for advancing R&D projects.

“We are ready to assist clients with their R&D efforts, with the mutual goal of getting novel safe and effective treatments to patients, faster,” Dr. Jung concludes.

Learn More about Syntekabio’s Offering www.syntekabio.com